Navigation Links
Isis Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
Date:2/28/2012

CARLSBAD, Calif., Feb. 28, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Cowen and Company's 32nd Annual Health Care Conference on Tuesday, March 06, 2012 at 10:40 a.m. ET at the Boston Marriot Copley Place.  

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
(Date:1/14/2014)... 14, 2014   NuAire , a manufacturer of ergonomically designed ... Hitachi Koki of Japan to sell ... America . NuAire will utilize its network of sales professionals ... Canada to offer assistance in application use, product benefits ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... Soligenix, Inc. (Soligenix or the Company) (OTC ... biopharmaceutical company, announced today promising preliminary results from ... or BDP) in a canine gastrointestinal acute radiation ... with SGX202 demonstrated statistically significant (p=0.04) improvement in ...
... BOTHELL, Wash., Jan. 18, 2011 BioLife Solutions, ... announced today that it has significantly increased its ... regenerative medicine industry.  The worldwide regenerative medicine market ... hospitals, which are developing cell and tissue-based products ...
Cached Medicine Technology:Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 2Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 3Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 4Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 5BioLife Solutions Increases 2011 Financial, Scientific, Technical Support of the Regenerative Medicine Industry 2BioLife Solutions Increases 2011 Financial, Scientific, Technical Support of the Regenerative Medicine Industry 3BioLife Solutions Increases 2011 Financial, Scientific, Technical Support of the Regenerative Medicine Industry 4BioLife Solutions Increases 2011 Financial, Scientific, Technical Support of the Regenerative Medicine Industry 5
(Date:4/18/2014)... School of Medicine researchers have been awarded two-year grants ... Nordisk announced this month. Of the 110 initial submissions ... Science Forum Program, only four projects were funded, three ... are Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; ... a professor of oncology, will use his $500,000 proof ...
(Date:4/18/2014)... 18, 2014) Benaroya Research Institute at Virginia Mason ... a particular molecule in metastatic breast cancer reduces both ... lung metastases. BRI scientists have found in models of ... by 60 - 80 percent and can keep the ... $1.8 million five-year grant comes from the National Cancer ...
(Date:4/18/2014)... (April 18, 2014) ― A new study in the ... patterns in health-related Google searches reveals a recurring pattern ... , Investigators from San Diego State University, ... Monday Campaigns, analyzed "healthy" Google searches (searches that included ... diet") originating in the U.S. from 2005 to 2012. ...
(Date:4/18/2014)... lead to potential new treatments for breaking the cycle ... Fibrosis, or scarring, is a hallmark of the disease, ... lead to serious organ damage and, in some cases, ... on findings made by Swati Bhattacharyya, PhD, research assistant ... specific protein plays in promoting fibrosis. , "Our ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3
... response leader Kroll Fraud Solutions will host webinars on preparing for ... Kroll data security experts. , ... Nashville TN (PRWEB) ... Kroll Fraud Solutions will host a free series of ...
... Company leads industry in providing medical transcriptionists with industry standard ... ... Forest, IL (PRWEB) February 5, 2009 -- Scribe Healthcare Technologies ... Base™ to the Scribe Complete™ medical documentation platform. This ...
... from Boston Medical Center (BMC) and Boston University School ... discharge failures. The Re-Engineered Discharge (RED) program reduces hospital ... percent, by redesigning the discharge workflow process. These findings ... of Internal Medicine . , One in five hospitalizations ...
... of the flu vaccine and other specialty medical products, has created ... , ... (Vocus) February 4, 2009 -- Nationwide Medical/Surgical ( ... specialty medical products, has created their 2009 annual list of how ...
... 4 Rev. Larry Snyder, president of ... today in the East Room of the White House ... Insurance Program Reauthorization Act of 2009. (Logo: ... critical health care access to children whose families do ...
... N.Y., Feb. 4 Attorney General Andrew Cuomo and ... his plan to establish a new not-for-profit organization to ... by health insurers who choose to pay out of ... with Attorney General Cuomo is the first involving an ...
Cached Medicine News:Health News:Kroll Fraud Solutions To Host Free Webinar Series on Preparing for and Responding to a Healthcare Data Breach 2Health News:Scribe Healthcare Technologies, LLC to Integrate BenchMark KB™ in Scribe Complete™ Medical Documentation Platform 2Health News:Researchers design re-engineered hospital discharge program to reduce rehospitalization 2Health News:Nationwide Medical/Surgical Unveils Flu Protection Tip Sheet 2Health News:Catholic Charities USA President Joins President Obama at Signing of Children's Health Insurance Legislation 2Health News:MVP Health Care is First Upstate New York Based Health Insurer to Agree with Attorney General Andrew Cuomo on Out-Of-Network Provider Payment Reform 2
... The programmer for the ITREL 3 ... programmer and the Model 7457 MemoryMod ... indicated for the treatment of chronic nausea ... drug therapies are not providing adequate relief ...
... Rapid diagnosis of influenza A ... important due to the availability ... diagnosis of influenza using Clearview ... can lead to reduced hospital ...
... ability of the visual system to ... are,some pathological conditions that reduce contrast ... test will help in the identification ... and reduced visual acuity often occur ...
...
Medicine Products: